MedHub has been expanded to work with a wider variety of insurance plans.
EvolutionIQ is expanding its medical summarization solution, MedHub, to all life, health, accident, and casualty lines of insurance.1 According to EvolutionIQ, MedHub is all able to provide claims professionals with actionable insights based upon the medical data it receives. It’s able to take data from multiple sources, such as a variety of complex case documents for a single medical claim, and normalize that data and reduce the amount of time spent on each claim.
In a press release Prudential vice president and head of group insurance claims Amanda Staples said, “MedHub enhances our claims professionals' ability to deeply understand their claimants' medical circumstances, and be a partner on their return to health journey. Using it inside our existing EvolutionIQ environment makes it a seamless expansion of our capabilities to better serve our claimants.”
In the same press release, EvolutionIQ chief product officer Benjamin Berry said, “The risk with any passive medical summary tool is it invites a copy/paste approach to time savings, and can potentially hurt claims outcomes. MedHub is entirely different, actively engaging claims professionals in the medical synthesis itself with access to essential data, context, and a timeline for informed decision-making. MedHub's focus on expert engagement is a pivotal component in EvolutionIQ's vision to become the #1 trusted source of medical insights and analysis in the insurance industry."
EvolutionIQ first announced MedHub in April of this year.2 At the time, it revealed that the technology used AI to provide its solutions. It was designed to work as a single workspace solution that can streamline the claims process.
In a press release issued at the time, Staples said, “MedHub enhances our claims professionals' ability to deeply understand their claimants' medical circumstances, and be a partner on their return to health journey. Using it inside our existing EvolutionIQ environment makes it a seamless expansion of our capabilities to better serve our claimants.”
In the same press release, Reliance Matrix chief claims officer Scott Boutin added, “EvolutionIQ's MedHub is the next advanced tool we are implementing on our journey of embracing technology and insight tools to support our claims guidance process. RelianceMatrix continues to be at the forefront of the industry, operationalizing cutting edge technology to enhance the service to our claimants through more effective and efficient tools for our claims examiners. EvolutionIQ's MedHub is a key resource in advancing our strategy."
Berry also said, “MedHub empowers Claims Professionals with access to essential data, context, and a timeline for informed decision-making.MedHub is a pivotal component in EvolutionIQ's vision to become the #1 trusted source of medical insights and analysis in the insurance industry.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.